Cadott Pharmacy Enters Settlement to Resolve Civil Allegations Regarding the Controlled Substances Act

Friday, April 29th, 2022 -- 11:01 AM

Timothy M. O’Shea, United States Attorney for the Western District of Wisconsin, announced that Cadott Miller Pharmacy, Ltd., located in Cadott, entered into a settlement agreement to pay $20,000 to resolve civil allegations that it violated the Controlled Substances Act by dispensing controlled substances outside the usual course of professional pharmacy practice, among other CSA violations.

As a registrant with the U.S. Drug Enforcement Administration, the CSA required the pharmacy to be both knowledgeable of and to adhere to federal and state statutes and regulations concerning the receipt, storage, recordkeeping, distribution, dispensing, and destruction of controlled substances.

Between 2017 and 2019, the DEA executed several administrative inspection warrants to review the pharmacy’s operations. As part of the inspections, the DEA investigated the pharmacy’s practices regarding the receiving, dispensing, and recordkeeping of controlled substances.

On December 17, 2019, after determining the pharmacy’s compliance measures were unsuccessful, DEA served an immediate suspension order of the pharmacy’s DEA Certificate of Registration, and Cadott Miller Pharmacy voluntarily surrendered its DEA registration on January 7, 2020, for cause. As a result, the pharmacy has been unable to dispense controlled substances.

According to the government’s allegations set forth in the settlement agreement, Cadott Miller Pharmacy dispensed controlled substances outside the usual course of professional pharmacy practice by filling combinations of controlled substances and medications that have no legitimate medical purpose, are highly addictive, and were specifically combined to create or enhance abusive and euphoric effects.

In addition, the government alleged that the pharmacy dispensed controlled substances with no valid prescription, provided unauthorized early refills, and dispensed Schedule II controlled substances for opioid dependence, which is prohibited under federal law.

The settlement agreement states CSA allegations only; Cadott Miller Pharmacy denies the allegations.

Feel free to contact us with questions and/or comments.